National guidelines for treatment of diabetic retinopathy: Second edition of the national guidelines for treatment of diabetic retinopathy;Nationale Versorgungsleitlinie (NVL) Diabetische Retinopathie: 2. Auflage der NVL zur Therapie der diabetischen Retinopathie

Ophthalmologe

Volumn 113, Issue 7, 2016, Pages 623-638

  Ziemssen, F ^a   Lemmen, K ^b   Bertram, B ^c   Hammes, H P ^d   Agostini, H ^e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Augenarztpraxis   (Germany)

^c Augenarztpraxis   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Control examinations; Diabetes; Evidence based medicine; Macular edema; Screening

Indexed keywords

DIABETIC RETINOPATHY; EVIDENCE BASED MEDICINE; FOLLOW UP; GERMANY; HUMAN; PRACTICE GUIDELINE;

DIABETIC RETINOPATHY; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; GERMANY; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84976435973     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-016-0315-8     Document Type: Article

References (89)

1. Arbeitsgemeinschaft der Wissenschaftlichen medizinischen Fachgesellschaften (AWMF) – Ständige Kommission Leitlinien AWMF-Regelwerk „Leitlinien“. 1. Auflage 2012. http:/www.awmf.org/leitlinien/awmf-regelwerk.html. Zugegriffen: 5. Dez 15
2. Praetorius F (2005) Ärztliche Entscheidungsspielräume – durch Leitlinien eingeengt oder erweitert? Hess Arztebl 8:516–520
3. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV) (1997) Beurteilungskriterien für Leitlinien in der medizinischen Versorgung – Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung. Dtsch Arztebl 94(33):2154–2155
4. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2010) Programm für Nationale VersorgungsLeitlinien. Methoden-Report, 4. Auflage. www.versorgungsleitlinien.de/methodik/reports. Zugegriffen: 5. Dez 15
5. Rodwin VG (2003) The Health Care System under French National Health Insurance: Lessons for Health Reform in the United States. Am J Public Health 93(1):31–37
6. Cochrane Klassifikation. http://www.cochrane.de/de/evidenz-empfehlung. Zugegriffen: 14. Dez 2015
7. Harbour R (2001) A new system for grading recommendations in evidence based guidelines. BMJ 323(7308):334–336
8. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2005) Nationale VersorgungsLeitlinie Prävention und Therapie von Netzhautkomplikationen bei Diabetes – Langfassung, 1. Aufl. (Version 2.6.2005)
9. National Institute for Clinical Excellence (NICE). (2008) Type 2 Diabetes. National clinical guideline for management in primary and secondary care (update). London: Royal College Of Physicians. http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf. Zugegriffen am: 16. Jun 2016
10. American Academy of Ophthalmology (AAO) (2014) Preferred practice pattern: diabetic retinopathy. http://one.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-2014. Zugegriffen am: 16. Jun 2016
11. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). (2015) Nationale VersorgungsLeitlinie Prävention und Therapie von Netzhautkomplikationen bei Diabetes – Langfassung, 2. Auflage. www.netzhautkomplikationen.versorgungsleitlinien.de. Zugegriffen: 14. Dez 2015
12. Early Treatment Diabetic Retinopathy Study Research Group (ETDRS) (1991) Early photo-coagulation for diabetic retinopathy. ETDRS report num-ber 9. Early Treatment Diabetic Retinopathy Study Re-search Group. Ophthalmology 98(5 Suppl):766–785
13. DOG, RG, BVA (2013) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands: Therapie der diabetischen Makulopathie. Klin Monbl Augenheilkd 230(6):614–628
14. Hirai FE, Tielsch JM, Klein BE et al (2011) Ten-year change in vision-related quality of life in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 118(2):353–358
15. Hirneiss C, Neubauer AS, Tribus C et al (2006) „Value-based medicine“ in der Augenheilkunde. Ophthalmologe 103(6):493–500
16. Brown MM, Brown GC, Sharma S et al (2002) Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 120(4):481–484
17. Fenwick EK, Xie J, Pesudovs K et al (2012) Assessing disutility associated with diabetic retinopathy, diabetic macular oedema and associated visual impairment using the vision and quality of Life Index. Clin Exp Optom 95(3):362–370
18. IDF Diabetes Atlas, 7th edition 2015. www.diabetesatlas.org. Zugegriffen am: 16. Jun 2016
19. Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme, Hagen B, Altenhofen L et al (2014) Qualitätssicherungsbericht 2013. Disease-Management-Programme in Nordrhein. Brustkrebs, Diabetes mellitus Typ 1/Typ 2, Koronare Herzkrankheit, Asthma/COPD. Nordrheinische Gemeinsame Einrichtung DMP, Düsseldorf (http://www.kvno.de/downloads/quali/qualbe_dmp13.pdf.). Zugegriffen am: 16. Jun 2016
20. Icks A, Rathmann W, Haastert B et al (2006) Versorgungsqualität und Ausmass von Komplikationen an einer bevölkerungsbezogenen Stichprobe von Typ 2‑Diabetespatienten. Der KORA-Survey 2000. Dtsch Med Wochenschr 131(3):73–78
21. Hesse L, Grusser M, Hoffstadt K et al (2001) Populationsbezogene Erhebung zur diabetischen Retinopathie in Wolfsburg. Ophthalmologe 98(11):1065–1068
22. Blum M, Kloos C, Müller N et al (2007) Prävalenz der diabetischen Retinopathie. Ophthalmologe 104(6):499–494
23. Diabetes-Patienten-Verlaufsdokumentation (DPV), Kompetenznetz Diabetes mellitus, Hammes HP et al (2015) Risk Factors for Retinopathy and DME in Type 2 Diabetes-Results from the German/Austrian DPV Database1. PLoS ONE 10(7):e0132492
24. Böhler S, Pittrow D, Pieper L et al (2006) Diabetes mellitus in der primärärztlichen Versorgung: Häufigkeit von mikro- und makrovaskulären Komplikationen – Ergebnisse der DETECT Studie. 41. Jahrestagung der Deutschen Diabetes-Gesellschaft. Diabet Stoffwechs 1(S1):1–A315
25. Looker HC, Nyangoma SO, Cromie DT et al (2014) Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. Br J Ophthalmol 98(6):790–795
26. Ziemssen F, Marahrens L, Roeck D, Comment on Leese et al (2015) Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals. Diabetes Care 38:488–494 (Diabetes Care. 2015; 38(12): e207–8)
27. Raum P, Lamparter J, Ponto KA et al (2015) Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study. PLoS ONE 10(6):e0127188
28. Kim DH, Grodstein F, Newman AB, Chaves PH, Odden MC, Klein R, Sarnak MJ, Patel KV, Lipsitz LA (2014) Prognostic implications of microvascular and macrovascular abnormalities in older adults: cardiovascular health study. J Gerontol A Biol Sci Med Sci 69(12):1495–1502
29. Bertram B, Gante C, Hilgers RD (2013) Zunahme der Untersuchungen wegen Katarakt, Glaukom, diabetischer Retinopathie und Makuladegeneration. Ophthalmologe 111(8):757–764
30. Claessen H, Genz J, Bertram B et al (2012) Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. Eur J Epidemiol 27(7):519–524
31. Finger RP, Bertram B, Wolfram C et al (2012) Blindheit und Sehbehinderung in Deutschland. Leichter Rückgang der Prävalenz. Dtsch Arztebl 109(27–28):484–489
32. Echouffo-Tcheugui JB, Ali MK, Roglic G, Hayward RA, Narayan KM (2013) Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. Diabet Med 30(11):1272–1292
33. Virk SA, Donaghue KC, Wong TY, Craig ME (2015) Interventions for Diabetic Retinopathy in Type 1 Diabetes: Systematic Review and Meta-Analysis. Am J Ophthalmol 160(5):1055–1064 (Nov)
34. Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564
35. Bays HE, Bazata DD, Clark NG, Gavin JR 3rd, Green AJ, Lewis SJ, Reed ML, Stewart W, Chapman RH, Fox KM, Grandy S (2007) Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). BMC Public Health 7:277
36. Navin CTJ, Stewart WJA, Parkinson L, Sibbritt DW, Byles JE (2015) Identification of diabetes, heart disease, hypertension and stroke in mid- and older-aged women: Comparing self-report and administrative hospital data records. Geriatr Gerontol Int 16(1):95–1613
37. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ (2004) Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 57(10):1096–1103
38. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN (2008) DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial–revisited. Diabetes 57(4):995–1001
39. DCCT/EDIC Research Group, Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, Klein R, Cleary PA, Lachin JM, Nathan DM (2015) Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med 372(18):1722–1733
40. Bianchi C, Del Prato S (2011) Metabolic memory and individual treatment aims in type 2 diabetes–outcome-lessons learned from large clinical trials. Rev Diabet Stud 8(3):432–440
41. Evans M, Crane M, Katz TA (2015) Effect of baseline haemoglobin A1c and on-treatment blood pressure at week 100 in the VIVID and VISTA studies. IDF World Diabetes Congress., S 116
42. Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L (2015) Influence of Glycosylated hemoglobin on the efficacy of Ranibizumab for diabetic macular edema: A post hoc analysis of the RIDE/RISE trials. Ophthalmology 122(8):1573–1579
43. Ziemssen F, Spital G (2014) Refining the treatment parameters of diabetic retinopathy: new prospects and limitations on the horizon. J Diabetes Complications 28(2):119
44. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38(1):140–149
45. Arnold LW, Wang Z (2014) The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J‑shaped: a meta-analysis of observational studies. Rev Diabet Stud 11(2):138–152
46. Gorst C, Kwok CS, Aslam S et al (2015) Long-term Glycemic variability and risk of adverse outcomes: A systematic review and meta-analysis. Diabetes Care 38(12):2354–2369
47. Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN (2015) Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev 1:CD006127
48. Man RE, Sasongko MB, Wang JJ, MacIsaac R, Wong TY, Sabanayagam C, Lamoureux EL (2015) The association of estimated Glomerular filtration rate with diabetic Retinopathy and macular edema. Invest Ophthalmol Vis Sci 56(8):4810–4816
49. Park YH, Shin JA, Han JH, Park YM, Yim HW (2015) The association between chronic kidney disease and diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008–2010. PLoS ONE 7(4):e0125338
50. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL (1989) The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 96(10):1501–1510
51. Agarwal R, Debella YT, Giduma HD et al (2012) Long-term retinal, renal and cardiovascular outcomes in diabetic chronic kidney disease without proteinuria. Nephrol Dial Transplant 27(1):310–317
52. Girach A, Vignati L (2006) Diabetic microvascular complications–can the presence of one predict the development of another? J Diabet Complications 20(4):228–237
53. Kramer CK, Rodrigues TC, Canani LH et al (2011) Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care 34(5):1238–1244
54. Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD (2014) Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med 160(1):18–29
55. Virgili G, Menchini F, Casazza G et al (2015) Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev 1:CD008081
56. Khan AI, Mohamed MD, Mann SS, Hysi PG, Laidlaw DA (2015) Prevalence of vitreomacular interface abnormalities on spectral domain optical coherence tomography of patients undergoing macular photocoagulation for centre involving diabetic macular oedema. Br J Ophthalmol 99(8):1078–1081
57. Hirano T, Iesato Y, Toriyama Y, Imai A, Murata T (2014) Detection of fovea-threatening diabetic macular edema by optical coherence tomography to maintain good vision by prophylactic treatment. Ophthalmic Res 52(2):65–73
58. Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS, Bressler NM, Danis RP, Kinyoun JL, Nguyen QD, Bhavsar AR, Gottlieb J, Pieramici DJ, Rauser ME, Apte RS, Lim JI, Miskala PH (2007) Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114(3):525–536
59. Bressler NM, Miller KM, Beck RW, Bressler SB, Glassman AR, Kitchens JW, Melia M, Schlossman DK (2012) Diabetic retinopathy clinical research network. Observational study of subclinical diabetic macular edema. Eye (Lond) 26(6):833–840
60. Taylor-Phillips S, Mistry H, Leslie R et al (2015) Extending the diabetic retinopathy screening interval beyond 1 year: systematic review. Br J Ophthalmol 100(1):105–114
61. Soto-Pedre E, Pinies JA, Hernaez-Ortega MC (2015) External validation of a risk assessment model to adjust the frequency of eye-screening visits in patients with diabetes mellitus. J Diabetes Complications 29(4):508–511
62. Wu B, Li J, Wu H (2015) Strategies to screen for diabetic Retinopathy in chinese patients with newly diagnosed type 2 diabetes: a cost-effectiveness analysis. Medicine (Baltimore) 94(45):e1989
63. Lund SH, Aspelund T, Kirby P, Russell G, Einarsson S, Palsson O, Stefánsson E (2015) Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs. Br J Ophthalmol 100(1):683–687
64. Early Treatment Diabetic Retinopathy Study Research Group (ETDRS) (1991) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. early treatment diabetic Retinopathy study research group. Ophthalmology 98(5 Suppl):766–785
65. Oh JH, Kim SW, Kwon SS et al (2015) The change of macular thickness following single-session pattern scan laser panretinal photocoagulation for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 253(1):57–63
66. Soman M, Ganekal S, Nair U et al (2012) Effect of panretinal photocoagulation on macular morphology and thickness in eyes with proliferative diabetic retinopathy without clinically significant macular edema. Clin Ophthalmol 6:2013–2017
67. Lee SB, Yun YJ, Kim SH et al (2010) Changes in macular thickness after panretinal photocoagulation in patients with severe diabetic retinopathy and no macular edema. Retina 30(5):756–760
68. Evans JR, Michelessi M, Virgili G (2014) Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev 24(11):CD011234
69. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW (2015) Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA 314(20):2137–2146
70. Mohamed QA, Ross A, Chu CJ (2011) Diabetic retinopathy (treatment). BMJ Clin Evid 2011. doi:10.1136/bmj.3.5881.636-a
71. Virgili G, Parravano M, Menchini F et al (2014) Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 10:CD007419
72. Ford JA, Lois N, Royle P et al (2013) Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open 3(3):e002269
73. Haritoglou C, Kernt M, Wolf A (2015) Diabetic maculopathy. Ophthalmologe 112(10):871–886
74. Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4):615–625
75. RISE and RIDE Research Group, Nguyen QD, Brown DM (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789–801
76. Korobelnik JF, Do DV, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121(11):2247–2254
77. Elman MJ, Ayala A, Bressler NM et al (2014) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5‑year randomized trial results. Ophthalmology 122(2):375–381
78. Pearce I, Banerjee S, Burton BJ, Chakravarthy U, Downey L, Gale RP, Gibson J, Pagliarini S, Patel J, Sivaprasad S, Andrews C, Brittain C, Warburton J (2015) RELIGHT study group. Ranibizumab 0.5mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, Multicenter, phase IIIB RELIGHT study. Ophthalmology 122(9):1811–1819
79. Ishibashi T, Li X, Koh A, Lai TY, Lee FL, Lee WK, Ma Z, Ohji M, Tan N, Cha SB, Shamsazar J, Yau CL, REVEAL Study Group (2015) The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. Ophthalmology 122(7):1402–1401
80. Avery RL, Gordon GM (2015) Systemic safety of prolonged monthly anti-vascular Endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis. JAMA Ophthalmol 29:1–9 (Oct)
81. Hecht H, Hörichs J, Sheldon S, Quint J, Bowers A (2015) The effects of simulated vision impairments on the cone of gaze. Atten Percept Psychophys 77(7):2399–2408
82. Geringswald F, Herbik A, Hofmüller W, Hoffmann MB, Pollmann S (2015) Visual memory for objects following foveal vision loss. J Exp Psychol Learn Mem Cogn 41(5):1471–1484
83. Bass EB, Marsh MJ, Mangione CM, Bressler NM, Childs AL, Dong LM, Hawkins BS, Jaffee HA, Miskala P (2004) Submacular Surgery Trials Research Group. Patients’ perceptions of the value of current vision: assessment of preference values among patients with subfoveal choroidal neovascularization–The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6. Arch Ophthalmol 122(12):1856–1867
84. Kalinowski MA (2008) „Eye“ dentifying vision impairment in the geriatric patient. Geriatr Nurs 29(2):125–132
85. Chaudry I, Brown GC, Brown MM (2015) Medical student and patient perceptions of quality of life associated with vision loss. Can J Ophthalmol 50(3):217–224
86. Dettmeyer R (2006) Medizin & Recht für Ärzte, 2. Aufl. Springer, Berlin
87. Parzeller M, Wenk M, Zedler B, Rothschild M (2007) Patient Information and Informed Consent before and after Medical Intervention. Dtsch Arztebl 104(9):576
88. Ahmadian L, Massof R (2008) Does functional vision behave differently in low-vision patients with diabetic retinopathy?–A case-matched study. Invest Ophthalmol Vis Sci 49(9):4051–4057
89. Lamoureux EL, Hassell JB, Keeffe JE (2004) The impact of diabetic retinopathy on participation in daily living. Arch Ophthalmol 122(1):84–88